Skip to search formSkip to main contentSkip to account menu

0.09 ML pegaptanib 3.33 MG/ML Prefilled Syringe [Macugen]

Known as: 0.09 ML Macugen 3.33 MG/ML Prefilled Syringe, Macugen 3.33 MG/ML Prefilled Syringe, 90 MCL, PEGAPTANIB SODIUM 3.47 mg in 1 mL INTRAVITREAL INJECTION, SOLUTION [Macugen] 
National Institutes of Health

Related topics

Related topics

9 relations
Hydrochloric AcidMacugenPegaptanib SodiumPrefilled Syringe

Broader (1)

pegaptanib Prefilled Syringe [Macugen]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
De novo tertiary structure prediction using RNA123—benchmarking and application to Macugen
AbstractThe present benchmarking study utilizes the RNA123 program for de novo prediction of tertiary structures of a set of 50… 
Review
2014
Review
2014
PEGylation and its impact on the design of new protein-based medicines.
PEGylation is the covalent conjugation of PEG to therapeutic molecules. Protein PEGylation is a clinically proven approach for… 
Review
2012
Review
2012
Treatment of Intractable Diabetic Macular Edema with Pegaptanib Versus Bevacizumab, Both in Combination with Dexamethasone
Background . Diabetic macular edema is a significant cause of vision loss, and some patients do not respond optimally to existing… 
2010
2010
Monotherapie der exsudativen altersbedingten Makuladegeneration bei kardiovaskulären Risikopatienten
ZusammenfassungHintergrundMit der intravitrealen Applikation von Ranibizumab (Lucentis®) oder Pegaptanib (Macugen®) stehen… 
2009
2009
[Initial and unique treatment of macular edema due to branch retinal vein occlusion with antiangiogenic agents. A comparative pilot study].
Dear Sir, Macular edema (ME) is the main cause of loss of vision associated to non-ischemic occlusion of the retinal venous… 
2008
2008
Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema
PurposeEvaluate the efficacy of intravitreal pegaptanib sodium (Macugen®) in refractory pseudophakic cystoid macular oedema (CME… 
2007
2007
Treatment of exudative age-related macular degeneration: many factors to consider.
2006
2006
Evaluation of Intravitreal Application of Pegaptanib Sodium (Macugen®) on Laser–Induced CNV in Cynomolgus Monkeys
2006
2006
[Pegaptanib (Macugen®) for age-related macular degeneration (AMD)]
2006
2006
Erste Ergebnisse über intravitreale Macugen-Injektionen bei feuchter AMD
Hintergrund: Bisher gab es nur zwei Moglichkeiten zur Behandlung der choroidalen Neovaskularisation bei altersbedingter… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)